Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/2013
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dorati, Cristian | es |
dc.contributor.author | Mordujovich-Buschiazzo, Perla | es |
dc.contributor.author | Buschiazzo, Héctor | es |
dc.contributor.author | Marin, Gustavo H. | es |
dc.date.accessioned | 2020-12-29T13:34:03Z | - |
dc.date.available | 2020-12-29T13:34:03Z | - |
dc.date.issued | 2020-10-21 | - |
dc.identifier.uri | http://sgc.anlis.gob.ar/handle/123456789/2013 | - |
dc.identifier.uri | http://rasp.msal.gov.ar/rasp/articulos/vol12supl/REV_DoratE9.pdf | - |
dc.description | Fil: Dorati, Cristian. Universidad Nacional de La Plata. Centro Universitario de Farmacología. Centro colaborador para el Uso Racional de los Medicamentos OMS/OPS; Argentina. | es |
dc.description | Fil: Mordujovich-Buschiazzo, Perla. Universidad Nacional de La Plata. Centro Universitario de Farmacología. Centro colaborador para el Uso Racional de los Medicamentos OMS/OPS; Argentina. | es |
dc.description | Fil: Buschiazzo, Héctor. Universidad Nacional de La Plata. Centro Universitario de Farmacología. Centro colaborador para el Uso Racional de los Medicamentos OMS/OPS; Argentina. | es |
dc.description | Fil: Marin, Gustavo H. Universidad Nacional de La Plata. Centro Universitario de Farmacología. Centro colaborador para el Uso Racional de los Medicamentos OMS/OPS; Argentina. | es |
dc.description.abstract | INTRODUCTION: Although there is a biological plausibility for the use of remdesivir in viral infections such as that caused by the new SARS-CoV-2 coronavirus, the veritable place of this medicine in COVID-19’s pandemic will be given by its therapeutic efficacy evidenced by clinical trials. The aim of this review is to analyze the scientific information available to date about the place of remdesivir in the treatment of patients with COVID-19. METHODS: a search for information on the efficacy and safety of remdesivir was performed conducted in biomedical databases, health technology evaluation reports, websites of the ministries of health, PanAmerican Health Organization and World Health Organization’s documents and drug regulatory agencies, considering the type of study, methodology, variables, end points proposed and results obtained. RESULTS: Currently, the greatest evidence comes from Adaptive COVID-19 Treatment Trial (ACTT-1) clinical trial. Preliminary results show that the average recovery time was 11 days in the remdesivir group, compared to 15 days in the placebo group. No statistically significant difference in mortality was observed. The safety profile of remdesivir shows elevated liver enzymes, renal failure, and / or hypotension at the time of infusion. CONCLUSION: the information available to date does not provide quality evidence to recommend a routine use of remdesivir for all patients with COVID-19. New clinical trials are necessary to validate the use of this medicine in this indication. | es |
dc.format | - | |
dc.language.iso | es | es |
dc.publisher | Ministerio de Salud Argentina | es |
dc.relation.ispartof | Revista Argentina de Salud Pública | es |
dc.rights | Open Access | - |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Revista Argentina de Salud Pública 2020; 12 Supl COVID-19: e9 | - |
dc.subject | Infecciones por Coronavirus | es |
dc.subject | COVID19 | es |
dc.subject | Antivirales | es |
dc.subject | Medicina Basada en la Evidencia | es |
dc.subject | Quimioterapia | es |
dc.title | Remdesivir : cuál es la evidencia para su utilización en el tratamiento de la infección por COVID-19 | es |
dc.title.alternative | Remdesivir: what is the evidence for its use in the treatment of COVID-19 infection? | es |
dc.type | Artículo | es |
dc.rights.license | Creative Commons Attribution 4.0 International License | - |
anlis.essnrd | 1 | - |
item.cerifentitytype | Publications | - |
item.openairetype | Artículo | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | es | - |
Appears in Collections: | Revista Argentina de Salud Pública |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Rev Argent Salud Pública_2020_12 Supl COVID-19_e9.pdf | Artículo en español | 583.87 kB | Adobe PDF | View/Open |
Google ScholarTM
Check
This item is licensed under a Creative Commons License